Company & Sponsor Intelligence

Sumitomo Pharma Co., Ltd.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting0

Completed1

Countries2

Therapeutic footprint

schizophrenia

Indexed studies

NCT02335658Long-term Study of DSP-5423P in Patients With Schizophrenia
schizophrenia · JapanPHASE3

NCT04825860A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
schizophrenia · ChinaPHASE2, PHASE3

NCT05359081A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
schizophrenia · JapanPHASE3

Intelligence layer updated: 2026-10-15 06:14:04.252491+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →